SG11201805913QA - New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them - Google Patents
New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA SG 11201805913Q A SG11201805913Q A SG 11201805913QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- utca
- berkshire
- budapest
- pct
- Prior art date
Links
- 150000003863 ammonium salts Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 241001581492 Attila Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Cephalosporin Compounds (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization MD 1111101110101011111 HO 11111011101110110111 HO HAIM III International Bureau ... ...... .Y1 j (10) International Publication Number (43) International Publication Date ..... ...,/ WO 2017/125224 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: BALINT, Balizs; Lehel utca 18, 2151 Hit (HU). SIPOS, C07F 9/6561 (2006.01) A61K 31/519 (2006.01) Szabolcs; Roppentyil utca 21-23., A epillet 3/10, H-1139 A61P 35/00 (2006.01) C07D 495/04 (2006.01) Budapest (HU). A61K 31/661 (2006.01) (81) Designated States (unless otherwise indicated, for every (21) International Application Number: kind of national protection available): AE, AG, AL, AM, PCT/EP2016/081688 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (22) International Filing Date: DO, 19 December 2016 (19.12.2016) HN, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (25) Filing Language: English KP, MD, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (26) Publication Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (30) Priority Data: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 16/50411 19 January 2016 (19.01.2016) FR TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (71) Applicants: LES LABORATOIRES SERVIER [FR/FR]; 35 me de Verdun, 92284 Suresnes (FR). VER- (84) Designated States (unless otherwise indicated, for every NALIS (R&D) LIMITED [GB/GB]; 100 Berkshire Place, kind of regional protection available): ARIPO (BW, GH, Wharfedale Road, Berkshire, Winnersh Berkshire RG41 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 5RD (GB). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, — (72) Inventors: PACZAL, Attila; Orjarat utca 95., H-1158 DK, EE, ES, FI, FR, GB, GR, HR, HU, IF, IS, IT, LT, LU, — _ Budapest (HU). SZLAVIK, Zoltan; Kolto utca 2-4 D/2, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, = 1121 Budapest (HU). KOTSCHY, Andras; Almos Vezer SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, u.4, 2045 Torokbalint (HU). CHANRION, Maya; 14 rue GW, KM, ML, MR, NE, SN, TD, TG). = de la Galiote, Apt D441, 92130 Issy Les Moulineaux (FR). MARAGNO, Ana Leticia; 4, Allee Anastasi, 78290 Published: Croissy-sur-Seine (FR). GENESTE, Olivier; Batiment A, — with international search report (Art. 21(3)) = 17, rue Crevel Duval, 92500 Rueil Malmaison (FR). DE- = MARLES, Didier; 21 me du Lievre, 45430 Checy (FR). = (54) Title: NEW AMMONIUM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COM- _ = POSITIONS CONTAINING THEM = = H 3 C, , 0 N ---.-- \"* . = = I N i -: \" . '\"--,, = 1 0 = 0 - e ll R 3 R Z (I) 11 O R 4 • ii- ei ei kin ei ,-1 Y O Rl • IN ,-1 0 (57) : Compounds of formula (I): wherein R I , R, R 2 3 , R 4 , R 5 , R 6 and ei Y are as defined in the description. Medicaments. 0
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1650411A FR3046792B1 (en) | 2016-01-19 | 2016-01-19 | NOVEL AMMONIUM DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| PCT/EP2016/081688 WO2017125224A1 (en) | 2016-01-19 | 2016-12-19 | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201805913QA true SG11201805913QA (en) | 2018-08-30 |
Family
ID=55752504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201805913QA SG11201805913QA (en) | 2016-01-19 | 2016-12-19 | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them |
Country Status (43)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3037958B1 (en) * | 2015-06-23 | 2019-01-25 | Les Laboratoires Servier | NOVEL HYDROXY ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR3037956B1 (en) * | 2015-06-23 | 2017-08-04 | Servier Lab | NOVEL AMINO ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
| CA3049095C (en) * | 2017-01-06 | 2022-01-25 | Les Laboratoires Servier | Combination of a mcl-1 inhibitor and a taxane compound, uses and pharmaceutical compositions thereof |
| UY37560A (en) | 2017-01-06 | 2018-07-31 | Servier Lab | COMBINATION OF AN MCL-1 INHIBITOR AND A TAXAN COMPOUND, USES AND PHARMACEUTICAL COMPOSITIONS OF THIS |
| JP7186731B2 (en) | 2017-06-22 | 2022-12-09 | レ ラボラトワール セルヴィエ | Combinations of MCL-1 inhibitors with standard therapeutic treatments for hematologic cancers, their uses and pharmaceutical compositions |
| EP3652184A4 (en) | 2017-08-15 | 2020-05-20 | AbbVie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHOD FOR USE |
| CA3073113A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| WO2019035927A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| CN108424417B (en) * | 2017-12-21 | 2019-09-20 | 河南真实生物科技有限公司 | Thienopyrimidine derivatives, preparation method thereof and application in preparation of antitumor drugs |
| AR116635A1 (en) | 2018-10-15 | 2021-05-26 | Servier Lab | PROCESS FOR THE SYNTHESIS OF PIPERAZINIL-ETOXY-BROMOPHENIL DERIVATIVES AND THEIR APPLICATION IN THE PRODUCTION OF COMPOUNDS CONTAINING THEM |
| TWI849001B (en) | 2018-11-14 | 2024-07-21 | 法商施維雅藥廠 | Combination of a mcl-1 inhibitor and midostaurin, uses and pharmaceutical compositions thereof |
| US12129261B2 (en) * | 2018-12-06 | 2024-10-29 | Les Laboratoires Servier | Crystalline forms of a MCL-1 inhibitor, a process for their preparation and pharmaceutical compositions containing them |
| US20230092679A1 (en) | 2019-05-20 | 2023-03-23 | Novartis Ag | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| AR119156A1 (en) | 2019-06-17 | 2021-11-24 | Servier Lab | COMBINATION OF AN MCL-1 INHIBITOR AND A STANDARD MEDICAL CARE TREATMENT FOR BREAST CANCER, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF |
| US20230116602A1 (en) * | 2019-10-03 | 2023-04-13 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
| US20240042051A1 (en) | 2020-11-24 | 2024-02-08 | Francesca Rocchetti | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| WO2022216946A1 (en) * | 2021-04-07 | 2022-10-13 | California Institute Of Technology | Mcl1 inhibitors and uses thereof |
| EP4351564A1 (en) | 2021-06-11 | 2024-04-17 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| WO2022261310A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-body drug conjugates |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025126157A1 (en) | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650425A (en) * | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
| WO1998034583A2 (en) * | 1997-02-09 | 1998-08-13 | Pharmos Corporation | Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones |
| EP1768986A2 (en) * | 2004-06-29 | 2007-04-04 | Amgen Inc. | Furanopyrimidines |
| WO2009052145A1 (en) * | 2007-10-16 | 2009-04-23 | Wyeth | Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors |
| ES2616255T3 (en) * | 2008-04-30 | 2017-06-12 | National Health Research Institutes | Condensed bicyclic pyrimidine compounds as aurora kinase inhibitors |
| KR101703941B1 (en) * | 2008-11-10 | 2017-02-07 | 내셔날 헬스 리서치 인스티튜트 | Fused Bicyclic and Tricyclic Pyrimidine Compounds as Tyrosine Kinase Inhibitors |
| CN102464667B (en) * | 2010-11-03 | 2014-06-04 | 中国科学院上海药物研究所 | Five-membered heterocycle pyrimidine compounds, preparation method and application thereof |
| JP2016504988A (en) * | 2012-11-14 | 2016-02-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Imidazopyridine derivatives |
| SI2991987T1 (en) * | 2013-05-02 | 2018-08-31 | F. Hoffmann-La Roche Ag | Purine derivatives as cb2 receptor agonists |
| FR3015483B1 (en) * | 2013-12-23 | 2016-01-01 | Servier Lab | NOVEL THIENOPYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME |
-
2016
- 2016-01-19 FR FR1650411A patent/FR3046792B1/en not_active Expired - Fee Related
- 2016-12-19 HR HRP20192073TT patent/HRP20192073T1/en unknown
- 2016-12-19 TN TNP/2018/000239A patent/TN2018000239A1/en unknown
- 2016-12-19 SI SI201630558T patent/SI3405471T1/en unknown
- 2016-12-19 GE GEAP201614858A patent/GEP20207126B/en unknown
- 2016-12-19 ES ES16816667T patent/ES2760545T3/en active Active
- 2016-12-19 HU HUE16816667A patent/HUE048449T2/en unknown
- 2016-12-19 MY MYPI2018702472A patent/MY196352A/en unknown
- 2016-12-19 RS RS20191499A patent/RS59622B1/en unknown
- 2016-12-19 US US16/069,891 patent/US10457689B2/en active Active
- 2016-12-19 CU CU2018000073A patent/CU20180073A7/en unknown
- 2016-12-19 WO PCT/EP2016/081688 patent/WO2017125224A1/en not_active Ceased
- 2016-12-19 PT PT168166676T patent/PT3405471T/en unknown
- 2016-12-19 AU AU2016387870A patent/AU2016387870B2/en active Active
- 2016-12-19 ME MEP-2019-336A patent/ME03555B/en unknown
- 2016-12-19 UA UAA201808693A patent/UA123508C2/en unknown
- 2016-12-19 PE PE2018001293A patent/PE20190336A1/en unknown
- 2016-12-19 JP JP2018555822A patent/JP6871275B2/en active Active
- 2016-12-19 MA MA43639A patent/MA43639B1/en unknown
- 2016-12-19 CN CN201680080679.7A patent/CN108602841B/en active Active
- 2016-12-19 SG SG11201805913QA patent/SG11201805913QA/en unknown
- 2016-12-19 EA EA201891622A patent/EA036932B1/en unknown
- 2016-12-19 DK DK16816667.6T patent/DK3405471T3/en active
- 2016-12-19 MX MX2018008808A patent/MX376028B/en active IP Right Grant
- 2016-12-19 LT LT16816667T patent/LT3405471T/en unknown
- 2016-12-19 CA CA3011761A patent/CA3011761C/en active Active
- 2016-12-19 CR CR20180363A patent/CR20180363A/en unknown
- 2016-12-19 PL PL16816667T patent/PL3405471T3/en unknown
- 2016-12-19 RU RU2018129308A patent/RU2743098C2/en active
- 2016-12-19 MD MDE20181134T patent/MD3405471T2/en unknown
- 2016-12-19 BR BR112018014536-0A patent/BR112018014536B1/en active IP Right Grant
- 2016-12-19 EP EP16816667.6A patent/EP3405471B1/en active Active
- 2016-12-19 KR KR1020187023819A patent/KR102805983B1/en active Active
-
2018
- 2018-07-10 SV SV2018005722A patent/SV2018005722A/en unknown
- 2018-07-11 IL IL260550A patent/IL260550B/en active IP Right Grant
- 2018-07-12 PH PH12018501506A patent/PH12018501506A1/en unknown
- 2018-07-13 CL CL2018001908A patent/CL2018001908A1/en unknown
- 2018-07-16 CO CONC2018/0007443A patent/CO2018007443A2/en unknown
- 2018-07-17 EC ECSENADI201853634A patent/ECSP18053634A/en unknown
- 2018-07-17 NI NI201800076A patent/NI201800076A/en unknown
- 2018-07-17 ZA ZA2018/04770A patent/ZA201804770B/en unknown
- 2018-07-19 SA SA518392049A patent/SA518392049B1/en unknown
-
2020
- 2020-01-27 CY CY20201100072T patent/CY1122560T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201805913QA (en) | New ammonium derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810576QA (en) | New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201810629QA (en) | New piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201806863WA (en) | Tetracyclic pyridone compounds as antivirals | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201900077QA (en) | 1,3-dihydroxy-phenyl derivatives useful as immunomodulators | |
| SG11201909680UA (en) | Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl compounds | |
| SG11201809299QA (en) | Formulations of an lsd1 inhibitor | |
| SG11201407533SA (en) | Antiviral compounds | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201811416VA (en) | Crystalline solid forms of a bet inhibitor | |
| SG11201806544XA (en) | Compounds and methods of treating rna-mediated diseases | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201810371XA (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| SG11201900689RA (en) | Compounds and compositions and uses thereof | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201408617PA (en) | Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders | |
| SG11201908660RA (en) | N-substituted indole derivatives | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201808686VA (en) | Synthesis of indazoles |